Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
NCT04207775
·
clinicaltrials.gov ↗
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class
Conditions
Locally Advanced or Metastatic NSCLC
Sponsor
AstraZeneca